PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.
about
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsIcam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammationPoly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteinsInflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammationSynthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid)Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency.Insights into atherosclerosis using nanotechnologyPreparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib.The potential of nanomedicine therapies to treat neovascular disease in the retina.Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cellsNanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Distinct subcellular trafficking resulting from monomeric vs multimeric targeting to endothelial ICAM-1: implications for drug deliveryUtilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes.Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug deliveryStructure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging.Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisA fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and miceEffect of variation in hemorheology between human and animal blood on the binding efficacy of vascular-targeted carriers.PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrugIn Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid APolymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicinDifferential Impact of Plasma Proteins on the Adhesion Efficiency of Vascular-Targeted Carriers (VTCs) in Blood of Common Laboratory AnimalsSingle-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis.Targeted polymeric therapeutic nanoparticles: design, development and clinical translationMultifunctional nanorods serving as nanobridges to modulate T cell-mediated immunityTargeted immunomodulation using antigen-conjugated nanoparticles.Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review).Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery.Nanotechnology in interventional cardiology.Systematic review: the applications of nanotechnology in gastroenterology.Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.Concepts and practices used to develop functional PLGA-based nanoparticulate systemsAptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood.Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules.Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactorAnti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment.
P2860
Q26823789-2D781C16-BA42-4025-B45D-17D9979D4A56Q28540684-16222FD9-57D7-4ADB-9078-2CAC5376F72EQ30371205-01299005-BD31-4FEC-A3B5-05F0F39E7CD3Q30462815-CA1509E9-D56F-4AB4-B045-36B0431F703CQ33719218-DEA22740-F185-4193-A3A6-B235BCDF6538Q33761970-CE7ED972-C422-4D16-9D63-8ABC83CC39EEQ33824820-119192E7-9356-4A47-896D-06E88D27530FQ33852343-C9D85A1A-58D8-4479-8EC3-42EAA964BEC0Q34220590-CD81FA6C-95A7-455F-83BA-FA1789A287CEQ34280097-65F6806D-3160-4213-864C-50F07DBFF157Q34394867-C8D6FC84-5A69-4934-9B74-9233B62C41F6Q34447986-3BD64D54-AEC3-4EA7-A62C-FF5171774979Q34631547-ED9B5D61-7D41-4D13-847E-A3D336B4189BQ35001301-782BC8F1-E6D2-428B-BBF9-5267D28674C0Q35043797-96E8B66B-B1F8-40FF-B252-047F4FB82585Q35318199-9DE997BE-B225-40CF-994E-5A2E8B42305FQ35590324-EAB8C6B7-2EF5-44C9-8929-2A9A82A67086Q35710262-2A5DB796-E667-4C72-906A-C1542FB2EC8EQ35776839-2B2CB528-F019-44B3-8BAA-6740DAC00D8FQ35784267-452C568F-CB67-4523-AD45-FAC518D79EE0Q35972569-3A4B4001-5843-49E7-95A1-4C6E6A4DA681Q35981228-8B24F8AE-7B92-47A0-B5A7-9D779037D074Q36189723-90B95ED2-AB88-4D45-AD60-E9CC0AA562E0Q36207113-E8131E02-6D58-4208-9F26-45F2A4813F4DQ36900233-D46FFF62-D4A7-498C-A0AA-B514F11E3CA8Q36901719-E5567981-9DDB-433E-A205-97CF6355FFAEQ36934007-3168F09E-9B29-43AB-B71A-BFC6F059E2C0Q37679496-1FE71F6C-9C97-4BCB-8DF0-F07A1E169C39Q37705215-6C037241-8005-4787-99FB-2F5EE3E1FD2CQ37771030-8144970D-26D5-4A3A-AF90-64382038AEBFQ37804385-53F0F29C-39AA-4E4F-B41C-BC37FE78088FQ37900267-6CBD6B95-CE57-4075-98F2-6B07FD1FCBA8Q38017701-8D0EF364-FDE5-4C88-B051-008F22B3F6D4Q38067265-D1C764C6-A19A-4924-BC57-B40C97AEAAEAQ38086377-8B2DAFC2-56E9-4409-B330-FE463DF40D4DQ38311680-82F03A61-CAF4-4268-AD68-6A2B58CF7200Q38560337-B7711290-BB9B-46BD-8745-128A0BF80ECEQ38836304-544C3EEC-F5C6-433E-8EA1-361A578F901EQ39061982-FBF1F27B-E927-4B2B-B045-4FAC94CCF38DQ39444446-14403270-D43F-4F36-9FF2-93CF1058115C
P2860
PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PLGA nanoparticle--peptide con ...... ular cell-adhesion molecule-1.
@en
type
label
PLGA nanoparticle--peptide con ...... ular cell-adhesion molecule-1.
@en
prefLabel
PLGA nanoparticle--peptide con ...... ular cell-adhesion molecule-1.
@en
P2093
P2860
P356
P1476
PLGA nanoparticle--peptide con ...... ular cell-adhesion molecule-1.
@en
P2093
Chadarat Duangrat
Chuda Chittasupho
Cory Berkland
Teruna J Siahaan
P2860
P304
P356
10.1021/BC700227Z
P577
2007-11-13T00:00:00Z